Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Neutropenia Biologic Drug Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The neutropenia biologic drug treatment market size has exhibited substantial growth in recent years. It will grow from $14.78 billion in 2025 to $15.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The historical period’s expansion can be attributed to an increase in cancer chemotherapy utilization, the approval of filgrastim-based therapies, a rise in infection-related hospitalizations, the adoption of supportive oncology care, and the standardization of hospital protocols.
The market for biologic drug treatments targeting neutropenia is anticipated to experience robust expansion over the coming years. It is projected to reach $20.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period is driven by factors such as an expanding oncology patient population, increased biosimilar penetration, a rising demand for long-acting drug formulations, the broadening of outpatient cancer care services, and an increase in healthcare expenditure. Key trends foreseen include a greater utilization of G-CSF biologics, the growing adoption of long-acting biologic therapies, advancements in managing chemotherapy-induced neutropenia, a strategic focus on biosimilars for cost reduction, and the expansion of distribution through hospitals and oncology pharmacies.
Get A Free Sample Report With In-Depth Market Insights:
Neutropenia Biologic Drug Treatment Market Development Factors: What’s Supporting Demand?
The global increase in cancer cases is expected to drive the growth of the market for neutropenia biologic drugs. A rising incidence of cancer and an expanding number of individuals undergoing chemotherapy have resulted in more people developing neutropenia. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that in 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the worldwide increase in cancer incidence rates is anticipated to boost demand for the neutropenia biologic drug treatment market over the forthcoming years.
Neutropenia Biologic Drug Treatment Market Breakdown By Product Type And Application
The neutropenia biologic drug treatment market covered in this report is segmented –
1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim
2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Neutropenia Biologic Drug Treatment Market Transformation Trends: What Innovations Are Driving Change?
Major companies in the neutropenia biologic drug treatment sphere are developing biosimilars to provide more cost-effective alternatives to existing biologics. These biosimilars are biologic drugs crafted to be nearly identical to an already approved reference biologic, exhibiting no significant differences in safety or effectiveness. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, intended for treating and preventing febrile neutropenia in patients undergoing chemotherapy. It functions by binding to specific receptors on hematopoietic cells, stimulating the proliferation and differentiation of neutrophil precursors in the bone marrow. This action boosts the production of neutrophils, which are essential for combating infections, particularly in patients undergoing myelosuppressive chemotherapy, consequently lowering the incidence of febrile neutropenia linked to cancer treatments.
Neutropenia Biologic Drug Treatment Market Company Landscape And Competitive Strategy
Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.
View The Full Neutropenia Biologic Drug Treatment Market Report:
Neutropenia Biologic Drug Treatment Market Top Region By Revenue And Market Share
North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model